Boehringer Doubles Down On China With €70 Million Plant Upgrade, Sets Sights On Biosimilars In Shanghai
This article was originally published in PharmAsia News
Executive Summary
German firm looks to implement a “lean manufacturing” model to help offset rising costs in China.